ArticleStatistics in medicine2021
Incorporating survival data into case-control studies with incident and prevalent cases.
Article in Statistics in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sampling in the All of Us research program.BMC medical genomics · 2026Article
- The Relation of Multiple Sclerosis to Family History, Lifestyle, and Health Factors in Childhood and Adolescence: Findings of a Case-Control Study Nested Within the German National Cohort (NAKO) Study.Deutsches Arzteblatt international · 2025Observational
- Ambient ultraviolet A, ultraviolet B, and risk of melanoma in a nationwide United States cohort, 1984-2014.Journal of the National Cancer Institute · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Typically, case-control studies to estimate odds-ratios associating risk factors with disease incidence only include newly diagnosed cases. Recently proposed methods allow incorporating information on prevalent cases, individuals who survived from disease diagnosis to sampling, into cross-sectionally sampled case-control studies under parametric assumptions for the survival time after diagnosis. Here we propose and study methods to additionally use prospectively observed survival times from prevalent and incident cases to adjust logistic models for the time between diagnosis and sampling, the backward time, for prevalent cases. This adjustment yields unbiased odds-ratio estimates from case-control studies that include prevalent cases. We propose a computationally simple two-step generalized method-of-moments estimation procedure. First, we estimate the survival distribution assuming a semiparametric Cox model using an expectation-maximization algorithm that yields fully efficient estimates and accommodates left truncation for prevalent cases and right censoring. Then, we use the estimated survival distribution in an extension of the logistic model to three groups (controls, incident, and prevalent cases), to adjust for the survival bias in prevalent cases. In simulations, under modest amounts of censoring, odds-ratios from the two-step procedure were equally efficient as those estimated from a joint logistic and survival data likelihood under parametric assumptions. This indicates that utilizing the cases' prospective survival data lessens model dependencies and improves precision of association estimates for case-control studies with prevalent cases. We illustrate the methods by estimating associations between single nucleotide polymorphisms and breast cancer risk using controls, and incident and prevalent cases sampled from the US Radiologic Technologists Study cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.